# Japan Brucellosis Market > Japan Brucellosis Market Research Report By Species ( Brucella suis, Brucella abortus, Brucella melitensis, Brucella canis, others), By End-User (hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies, others), By Diagnosis (serological tests, molecular techniques, bone marrow biopsy, X-rays, computerized tomography (CT), magnetic resonance imaging (MRI), cerebrospinal fluid culture, echocardiography, others), By Treatment (antibiotics, vaccines, others), By Region - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.28% - **2024:** $ 24.66 Million - **2025:** $ 26.65 Million - **2035:** $ 48.19 Million - **Key Players:** Mitsubishi Tanabe Pharma Corporation (JP), Takeda Pharmaceutical Company Limited (JP), Astellas Pharma Inc. (JP), Daiichi Sankyo Company, Limited (JP), Otsuka Pharmaceutical Co., Ltd. (JP), Eisai Co., Ltd. (JP), Chugai Pharmaceutical Co., Ltd. (JP), Kyowa Kirin Co., Ltd. (JP) **Report ID:** MRFR/LS/51830-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/japan-brucellosis-market-53591 --- ## Market Summary ## **Japan Brucellosis Market Overview** As per MRFR analysis, the Japan Brucellosis Market Size was estimated at 10.68 (USD Million) in 2023.The Japan Brucellosis Market is expected to grow from 11.62(USD Million) in 2024 to 43.68 (USD Million) by 2035. The Japan Brucellosis Market CAGR (growth rate) is expected to be around 12.789% during the forecast period (2025 - 2035). **Key Japan Brucellosis Market Trends Highlighted** The market for brucellosis in Japan is undergoing noteworthy developments, mostly due to growing public awareness of zoonotic illnesses. The necessity for efficient surveillance and management of Brucellosis in cattle and other domestic animals has increased due to the growth of livestock husbandry and dairy production in rural areas. As the Japanese Ministry of Agriculture, Forestry, and Fisheries highlights the significance of disease preventive and control methods, government activities targeted at guaranteeing animal health are also driving the industry ahead. There are a lot of opportunities in the Japanese brucellosis market, particularly for cutting-edge diagnostic equipment and vaccinations. There is an increasing need for innovative technology that can quickly detect and treat the illness. Furthermore, partnerships between public and private entities are opening the door for scientific breakthroughs that may enhance efforts to monitor and stop brucellosis epidemics. Additionally, there is growing interest in improving farmers' and veterinarians' knowledge and training, which could lower the prevalence of disease. increasingly integrated and cooperative methods to illness management are becoming increasingly prevalent, according to recent trends. As consumers' concerns about the effects of animal diseases on food quality grow, public health and food safety awareness efforts are becoming more widespread. In order to improve disease reporting and containment tactics, the Japanese government is concentrating on surveillance systems that comply with international health standards. All things considered, these patterns show a proactive approach to improving the general health and sustainability of cattle production in Japan as well as reducing the incidence of brucellosis. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Japan Brucellosis Market Drivers** **Increasing Awareness and Education on Brucellosis** In Japan, there is a growing emphasis on the awareness of Brucellosis among agricultural communities and healthcare professionals. The Ministry of Agriculture, Forestry and Fisheries has been actively promoting educational programs aimed at reducing the incidence of Brucellosis through better vaccination and livestock management practices. These initiatives contribute to a more informed public and create a demand for vaccination products and associated healthcare services. As public awareness grows, the Japan Brucellosis Market is expected to see significant developments, supported by educational efforts leading to increased demand for testing and treatment solutions. According to recent government reports, awareness campaigns can reduce disease incidence by up to 40%, indicating a robust avenue for market growth. **Government Initiatives and Regulatory Frameworks** The Japanese government has been proactive in addressing the challenges posed by infectious diseases, including Brucellosis, through stringent regulations and policies. For instance, the recent enhancement of livestock inspection protocols and vaccination mandates has led to a more stringent control over the spread of Brucellosis. This regulatory framework instills confidence among stakeholders in the Japan [Brucellosis Market](../../../reports/brucellosis-market-5159), fostering investment in innovative diagnostic tools and therapies. The Veterinary Authority in Japan has reported an annual increase in funding for veterinary services, which has risen by approximately 15% over the past three years, enhancing market potential. **Rising Incidence of Animal Diseases** The rising incidence of animal diseases in Japan has led to heightened concerns about the health of livestock and the potential economic impacts on the agricultural sector. Recent data reveal an increase in reported animal disease cases, including Brucellosis, prompting livestock producers to seek more effective vaccination and management solutions. The Japan Animal Health Association noted a 25% increase in demand for livestock vaccines specifically targeting Brucellosis and other zoonotic diseases due to these developments. This trend supports the growth of the Japan Brucellosis Market as it fosters increased investment in Research and Development and innovative solutions for disease management. **Japan Brucellosis Market Segment Insights** **Brucellosis Market species Insights** The Japan Brucellosis Market has shown robust growth owing to various species that are crucial in understanding the disease and its management. Among the species of Brucella, Brucella suis is predominantly associated with swine, and this species poses a considerable challenge for the livestock industry in Japan due to its impact on animal health and zoonotic potential. The prevalence of Brucella suis in pigs affects not only animal productivity but also indicates potential transfer risks to humans, especially in communities that consume pork. B. abortus, primarily known for its effects on cattle, is significant in the Japanese agricultural landscape as it can lead to reproductive issues in livestock, resulting in economic losses. Preventive measures in cattle herds are essential for maintaining herd health, thus being crucial in the dairy industry where the supply chain is tightly interlinked. B. melitensis, although less common in Japan compared to other species, remains critical to public health discussions because of its higher virulence in humans. The presence of B. melitensis underscores the importance of stringent health surveillance and control measures to prevent outbreaks. As Japan continues to enhance its food safety protocols and animal health regulations, understanding these species of Brucella is vital for mitigating potential risks to both agriculture and public health. Their distinct characteristics and impacts highlight the relevance of continued Research and Development efforts aimed at vaccines and diagnostics, which are necessary to address the challenges posed by each species. The Japan Brucellosis Market dynamics and developments showcase the need for a comprehensive approach, integrating veterinary health practices with public health strategies, while being cognizant of the economic implications associated with Brucella infections. Keeping the livestock industry in healthy contention with zoonotic disease management remains fundamental for sustainable agricultural practices in Japan. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Japan Brucellosis Market Key Players and Competitive Insights** The Japan Brucellosis Market is a specialized segment that deals with the management and treatment of brucellosis, a bacterial infection that affects both humans and animals. In this market, various pharmaceutical companies are competing to provide effective solutions through the development of vaccines, diagnostic tools, and therapeutics. The competitive landscape is shaped by several factors, including product innovation, regulatory approvals, distribution networks, and partnerships with healthcare providers. Given the complexity of the disease, which is primarily transmitted through livestock, the market players are focusing on delivering high-quality products and maintaining their market share amid the evolving healthcare needs and antimicrobial resistance issues prevalent in Japan. Eli Lilly and Company has a notable presence in the Japan Brucellosis Market. The company is recognized for its strong emphasis on research and development, resulting in innovative therapies and vaccines designed to combat brucellosis more effectively. Eli Lilly has established strategic alliances with various stakeholders, including academic institutions and local biotech firms, which enhances its capabilities in addressing the regional healthcare requirements. The firm benefits from its extensive distribution channels and a solid reputation for quality and reliability in the pharmaceutical sector, making its products a preferred choice among medical professionals in Japan for treating brucellosis and related conditions. Bristol-Myers Squibb is another significant player in the Japan Brucellosis Market, boasting a diverse portfolio of products that include advanced therapeutics aimed at infectious diseases. The company has invested in building a robust market presence through targeted marketing strategies and collaborations with local healthcare entities. Bristol-Myers Squibb’s strengths stem from its commitment to innovation and a strong focus on patient-centric solutions, which resonate well within the Japanese healthcare landscape. The company is actively engaged in mergers and acquisitions that bolster its capabilities and expand its reach in the region. These strategic moves not only enhance its product offerings but also solidify its position as a key player in addressing the challenges posed by brucellosis, thereby contributing to improved health outcomes in Japan. **Key Companies in the Japan Brucellosis Market Include:** - Eli Lilly and Company - Bristol-Myers Squibb - Noble Foods - Pfizer - Bayer - Cegelec - Heska Corporation - Merial - Genus - Boehringer Ingelheim - Merck & Co - Sanofi - AbbVie - Zoetis - Virbac **Japan Brucellosis****Market****Developments** Recent developments in the Japan Brucellosis Market indicate a growing focus on the prevention and control of this infectious disease among livestock, due to its implications on public health and the agricultural economy. Companies like Eli Lilly and Company, Pfizer, and Merck and Co have been actively engaged in Research and Development efforts for vaccines and treatments aimed at addressing brucellosis in cattle and other livestock. In terms of market activity, the valuation of companies such as Zoetis and Bayer has seen growth, driven by the increasing demand for animal health products and the rising incidence of brucellosis among livestock herds. Moreover, within the last few years, key players have noted changes in regulations, likely influenced by public health concerns following outbreaks documented in May 2022 and earlier notifications from the Ministry of Health, Labour, and Welfare in Japan. There have been no significant mergers or acquisitions reported among the specified companies within the brucellosis sector as of late 2023, indicating a stable market environment focused more on strategic partnerships and collaborations rather than consolidation. These ongoing trends emphasize the importance of integrated approaches in addressing veterinary public health issues in Japan. **Japan Brucellosis Market Segmentation Insights** **Brucellosis Market species Outlook** - Brucella suis - B. abortus - B. melitensis ## Market Drivers ### Government Policies and Regulations Government policies play a crucial role in shaping the Japan Brucellosis Market. The Japanese government has established stringent regulations regarding the control and prevention of brucellosis, which include mandatory vaccination programs for livestock and regular health inspections. These policies are designed to protect public health and ensure food safety, thereby fostering a conducive environment for market growth. The enforcement of these regulations is likely to increase the demand for [veterinary services](https://www.marketresearchfuture.com/reports/veterinary-service-market-42245) and products related to brucellosis management. Furthermore, the government's commitment to eradicating brucellosis from livestock populations may lead to increased funding for research and development in the Japan Brucellosis Market. ### Growing Consumer Awareness of Food Safety Consumer awareness regarding food safety is becoming increasingly prominent in Japan, which is positively impacting the Japan Brucellosis Market. As consumers demand higher standards for food safety, there is a growing emphasis on the health of livestock and the prevention of zoonotic diseases like brucellosis. This trend is prompting producers to adopt better management practices and invest in veterinary services to ensure the health of their animals. Consequently, the demand for brucellosis-related products, including vaccines and diagnostic tools, is likely to rise. The heightened focus on food safety is expected to drive growth in the Japan Brucellosis Market, as stakeholders respond to consumer expectations. ### Technological Advancements in Diagnostics Technological advancements in diagnostic tools are significantly influencing the Japan Brucellosis Market. The introduction of rapid and accurate diagnostic tests has improved the ability to detect brucellosis in livestock, facilitating timely intervention and treatment. These innovations not only enhance disease management but also contribute to the overall efficiency of livestock production. As farmers and veterinarians increasingly adopt these advanced diagnostic methods, the demand for related products and services is expected to rise. The integration of technology in disease detection and management is likely to be a key driver in the evolution of the Japan Brucellosis Market, ensuring better health outcomes for livestock. ### Rising Incidence of Brucellosis in Livestock The Japan Brucellosis Market is experiencing heightened attention due to the rising incidence of brucellosis in livestock. Reports indicate that the prevalence of this zoonotic disease among cattle and other livestock has been increasing, prompting the government to implement stricter monitoring and control measures. This trend is likely to drive demand for diagnostic tools and vaccines, as farmers and veterinarians seek to mitigate the impact of the disease on livestock health and productivity. The Japanese Ministry of Agriculture, Forestry and Fisheries has been actively involved in initiatives aimed at reducing the incidence of brucellosis, which further emphasizes the importance of addressing this issue within the Japan Brucellosis Market. ### Increased Collaboration Between Public and Private Sectors The Japan Brucellosis Market is witnessing increased collaboration between public and private sectors, which is fostering innovation and improving disease management strategies. Partnerships between government agencies, research institutions, and private companies are essential for developing effective vaccines and treatment options. This collaborative approach not only enhances the research and development capabilities within the market but also facilitates the dissemination of knowledge and best practices among stakeholders. As these partnerships strengthen, they are likely to lead to more comprehensive strategies for controlling brucellosis, ultimately benefiting the Japan Brucellosis Market and its stakeholders. ## Future Outlook The Japan Brucellosis Market is projected to grow at a 6.28% CAGR from 2025 to 2035, driven by increased awareness, advancements in diagnostics, and enhanced veterinary practices. **New opportunities:** - Development of mobile diagnostic units for rural areas - Investment in vaccine production facilities to meet demand - Partnerships with agricultural cooperatives for awareness campaigns By 2035, the market is expected to achieve robust growth, positioning itself as a leader in disease management. ## Segment Insights ### By Species: Brucella melitensis (Largest) vs. Brucella canis (Fastest-Growing) In the Japan brucellosis market, the distribution of market share among various species reveals that Brucella melitensis holds the largest share, primarily due to its prevalence in livestock and significant impact on dairy production. Following closely are Brucella abortus and Brucella suis, which are also substantial contributors but do not match the dominance of melitensis. Brucella canis, while smaller in overall share, is gaining traction owing to increasing awareness and diagnostic advancements. Growth trends within the species segment of the Japan brucellosis market are being primarily driven by heightened veterinary awareness and advancements in diagnostic technologies. The rising demand for safer livestock and the growing dairy industry significantly boost the market for Brucella melitensis. Conversely, Brucella canis is emerging rapidly, fueled by increasing pet ownership and the steady rise in zoonotic disease awareness, which are key factors contributing to its fast growth trajectory. Brucella melitensis (Dominant) vs. Brucella canis (Emerging) Brucella melitensis is recognized as the dominant species in the Japan brucellosis market due to its significant impact on both economic and health perspectives in livestock. This pathogen is historically linked to significant outbreaks in cattle, leading to extensive economic losses in dairy production. The robust veterinary practices and control measures in place have further cemented its place as the most impactful species. On the other hand, Brucella canis, which typically infects dogs, is considered an emerging concern. As pet ownership increases, so does the awareness of zoonotic diseases, placing Brucella canis in the spotlight. This species is now being prioritized for research and diagnostic development, reflecting its potential for growth in the market. ### By Diagnosis: Serological Tests (Largest) vs. Molecular Techniques (Fastest-Growing) In the diagnosis segment of the Japan brucellosis market, serological tests dominate with the largest market share, attributed to their widespread use due to ease of administration and cost-effectiveness. Following closely are molecular techniques, which, while holding a smaller share, are being rapidly adopted due to their enhanced accuracy and speed in results. The growth trends are influenced by increasing investments in advanced diagnostic technologies and rising awareness about brucellosis among healthcare providers. Molecular techniques are set to experience the fastest growth as they become more accessible and integrated into standard diagnostic protocols. This is driven by ongoing research and development, leading to innovations that improve diagnostic precision and reduce time to diagnosis, which is critical for patient management. Serological Tests (Dominant) vs. Molecular Techniques (Emerging) Serological tests are characterized by their high reliability and ease of deployment in clinical settings, making them a preferred choice among practitioners in the Japan brucellosis market. These tests are frequently utilized due to their ability to provide quick results and low operational costs. In contrast, molecular techniques, while currently an emerging segment, are gaining momentum due to advancements in technology that allow for rapid and accurate detection of brucella DNA. The growing preference for molecular methods is driven by the increasing demand for precision medicine and better treatment outcomes. As a result, while serological tests remain a dominant diagnostic method, molecular techniques are fast becoming crucial in evolving diagnostic landscapes. ### By Treatment: Antibiotics (Largest) vs. Vaccines (Fastest-Growing) The treatment segment in the Japan brucellosis market is primarily characterized by antibiotics, vaccines, and other treatment options. In this market, antibiotics hold the largest share, dominating the landscape due to their established efficacy in treating brucellosis infections. Vaccines, while currently a smaller segment, are rapidly gaining traction as awareness of preventive measures increases. This combination of treatment options illustrates a diversified approach to combatting brucellosis in the region. Growth trends in the Japan brucellosis market are driven by an increasing incidence of brucellosis, necessitating effective treatment solutions. Antibiotic treatments continue to see consistent demand, underpinned by clinical guidelines recommending their use. On the other hand, the vaccine segment is emerging as the fastest-growing area, propelled by innovation in vaccine development and heightened government initiatives aiming to reduce disease prevalence through preventive care. This dynamic reflects a shift towards a more comprehensive understanding of disease management. Antibiotics (Dominant) vs. Vaccines (Emerging) Antibiotics are the dominant treatment option within the Japan brucellosis market, valued for their immediate effectiveness in combating the infection. Their extensive use is supported by a strong clinical framework that emphasizes timely intervention. In contrast, vaccines represent an emerging but crucial segment, being explored vigorously for their potential to confer immunity and reduce transmission rates. This dual focus on immediate treatment and long-term prevention illustrates a balanced strategy employed in the market. As the healthcare landscape evolves, both segments are expected to coexist, with antibiotics addressing current infections while vaccines aim to prevent future occurrences. ### By End-User: Hospitals & Diagnostic Centers (Largest) vs. Academic Institutes (Fastest-Growing) In the Japan brucellosis market, hospitals and diagnostic centers dominate the end-user segment with a significant market share, as they are the primary entities for diagnosis and treatment of brucellosis. Their established infrastructure, skilled personnel, and the critical need for accurate diagnostics contribute to their strong position in the market. Academic institutes follow as a notable segment but are less dominant compared to hospitals, focusing on research and education in infectious diseases. The growth trends in this segment are influenced by increasing awareness of zoonotic diseases and the rising number of diagnostic tests performed. Hospitals and diagnostic centers are expanding their capabilities to provide rapid and accurate tests, enhancing their role in disease management. On the other hand, academic institutes are experiencing rapid growth due to collaborations with industry and government for research, making them the fastest-growing segment in this market. Hospitals & Diagnostic Centers (Dominant) vs. Academic Institutes (Emerging) Hospitals and diagnostic centers are positioned as the dominant force in the Japan brucellosis market, driven by their comprehensive services and critical role in diagnosing and managing brucellosis cases. Their ability to provide timely diagnosis and treatment makes them essential in controlling the disease spread. The increasing healthcare expenditure and emphasis on infectious disease management further bolster their market position. Conversely, academic institutes, while still emerging, are becoming increasingly relevant. Their focus on research, development of innovative diagnostic tools, and partnerships with pharmaceutical companies highlights their importance in advancing knowledge about brucellosis, thereby making them a vital part of the ecosystem aimed at combatting this infectious disease. ## Competitive Benchmarking The Brucellosis Market in Japan is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on regional expansion. Key players such as Mitsubishi Tanabe Pharma Corporation (Japan), Takeda Pharmaceutical Company Limited (Japan), and Astellas Pharma Inc. (Japan) are actively engaged in enhancing their market positions through various strategic initiatives. These companies appear to be leveraging their research and development capabilities to introduce novel therapies, thereby addressing unmet medical needs in the treatment of brucellosis. The collective efforts of these firms contribute to a dynamic environment where competition is not solely based on pricing but also on the efficacy and safety of new treatments. In terms of business tactics, localizing manufacturing and optimizing supply chains are becoming increasingly vital. The market structure is moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they often set the standards for product quality and innovation. This competitive structure suggests that while smaller firms may struggle to compete on a large scale, they can still carve out niches by focusing on specialized treatments or regional markets. In December 2025, Takeda Pharmaceutical Company Limited (Japan) announced a collaboration with a leading biotechnology firm to develop a new vaccine targeting brucellosis. This strategic move is likely to enhance Takeda's portfolio and position it as a leader in preventive measures against the disease. The partnership underscores the importance of innovation in addressing public health challenges and reflects a broader trend towards collaborative approaches in drug development. In November 2025, Astellas Pharma Inc. (Japan) launched a new treatment regimen for brucellosis that incorporates advanced drug delivery systems. This initiative not only demonstrates Astellas' commitment to improving patient outcomes but also highlights the growing trend of integrating technology into pharmaceutical solutions. The introduction of such innovative therapies may significantly alter treatment paradigms and enhance the company's competitive edge. In October 2025, Mitsubishi Tanabe Pharma Corporation (Japan) expanded its research facilities in Japan to focus on infectious diseases, including brucellosis. This expansion is indicative of the company's long-term strategy to bolster its R&D capabilities and respond to emerging health threats. By investing in infrastructure and talent, Mitsubishi Tanabe is positioning itself to lead in the development of next-generation therapies. As of January 2026, the competitive trends in the Brucellosis Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development processes. Strategic alliances are playing a crucial role in shaping the current landscape, as companies recognize the value of collaboration in fostering innovation. Looking ahead, it is anticipated that competitive differentiation will evolve, with a shift from price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This transition may ultimately lead to improved patient outcomes and a more resilient market. ## Recent News & Developments Recent developments in the Japan Brucellosis Market indicate a growing focus on the prevention and control of this infectious disease among livestock, due to its implications on public health and the agricultural economy. Companies like Eli Lilly and Company, Pfizer, and Merck and Co have been actively engaged in Research and Development efforts for vaccines and treatments aimed at addressing brucellosis in cattle and other livestock. In terms of market activity, the valuation of companies such as Zoetis and Bayer has seen growth, driven by the increasing demand for [animal health](https://www.marketresearchfuture.com/reports/animal-health-market-7163) products and the rising incidence of brucellosis among livestock herds. Moreover, within the last few years, key players have noted changes in regulations, likely influenced by public health concerns following outbreaks documented in May 2022 and earlier notifications from the Ministry of Health, Labour, and Welfare in Japan. There have been no significant mergers or acquisitions reported among the specified companies within the brucellosis sector as of late 2023, indicating a stable market environment focused more on strategic partnerships and collaborations rather than consolidation. These ongoing trends emphasize the importance of integrated approaches in addressing veterinary public health issues in Japan. ## Report Scope | MARKET SIZE 2024 | 24.66(USD Million) | | --- | --- | | MARKET SIZE 2025 | 26.65(USD Million) | | MARKET SIZE 2035 | 48.19(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.28% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Mitsubishi Tanabe Pharma Corporation (JP), Takeda Pharmaceutical Company Limited (JP), Astellas Pharma Inc. (JP), Daiichi Sankyo Company, Limited (JP), Otsuka Pharmaceutical Co., Ltd. (JP), Eisai Co., Ltd. (JP), Chugai Pharmaceutical Co., Ltd. (JP), Kyowa Kirin Co., Ltd. (JP) | | Segments Covered | Application, End Use, Distribution Channel, Product Type | | Key Market Opportunities | Increasing demand for advanced diagnostic tools and vaccines in the Japan Brucellosis Market. | | Key Market Dynamics | Rising regulatory scrutiny and advancements in diagnostic technologies shape Japan's Brucellosis market dynamics. | | Countries Covered | Japan | ## Frequently Asked Questions **Q: What is the current valuation of the Japan brucellosis market in 2024?** A: The overall market valuation was $29.59 Million in 2024. **Q: What is the projected market valuation for the Japan brucellosis market by 2035?** A: The projected valuation for 2035 is $63.17 Million. **Q: What is the expected CAGR for the Japan brucellosis market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 7.14%. **Q: Which companies are the key players in the Japan brucellosis market?** A: Key players include Zoetis Inc, Merck & Co Inc, Boehringer Ingelheim, Ceva Santé Animale, Virbac, Heska Corporation, Vetoquinol, and Phibro Animal Health Corporation. **Q: What are the main species segments in the Japan brucellosis market?** A: Main species segments include Brucella suis, Brucella abortus, Brucella melitensis, Brucella canis, and others. **Q: What was the market value for Brucella melitensis in 2024?** A: The market value for Brucella melitensis was $10.0 Million in 2024. **Q: What are the primary diagnostic methods used in the Japan brucellosis market?** A: Primary diagnostic methods include serological tests, molecular techniques, bone marrow biopsy, and X-rays. **Q: What is the market value for antibiotics in the treatment segment for 2024?** A: The market value for antibiotics in the treatment segment was $10.0 Million in 2024. **Q: Which end-user segments are prominent in the Japan brucellosis market?** A: Prominent end-user segments include hospitals & diagnostic centers, academic institutes, and pharmaceutical & biotechnology companies. **Q: What is the projected growth for the Brucella abortus segment by 2035?** A: The projected growth for the Brucella abortus segment is expected to reach $15.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/japan-brucellosis-market-53591*